Hopes of greatly speeding up the evaluation of new therapies by using tumour response to a short course of neoadjuvant treatment as a surrogate for clinical benefit have proved false and the sooner we recognise that the better. This is the message of the Guest Editorial written by Fatima Cardoso, Director of the Breast Unit at LisbonÂ’s Champalimaud Hospital.
Most people carrying harmful BRCA mutations only find out after they are diagnosed with cancer, and often not even then. Population screening is costly and the results can be hard to interpret. But should we do it anyway?
Understanding the impact of treating the mother on the long-term health of her unborn child has long been held back by logistical and ethical obstacles to
researching this rare patient population. FrĂ©dĂ©ric Amant took up the challenge.
The beta-carotene fiasco warned oncologists off suggesting supplements on the basis of observational studies. But with vitamin D now in the spotlight, how should doctors respond when their patients ask if it could help?
For many patients seeking access to treatments unavailable in their home country, the Cross-border Healthcare Directive turned out to be a bit of a disappointment. But a closer look shows it may help raise standards of care in ways that were not widely anticipated.
Can deep and close-knit collaboration between a handful of elite centres achieve what broader European research platforms and projects cannot?
When chemotherapy drugs leak from the veins it can cause serious injury to the
patient, greatly heighten their fears of undergoing future treatment cycles, and
undermine their trust in their medical team. Knowing how to assess and reduce
the risks, and what to do when things go wrong, is essential.
The patient rejects the Â‘standard of careÂ’. The oncologist cannot answer his question Â“How long do I have?Â” Is the treatment course they agree on Â‘second bestÂ’, or Â‘bestÂ’?